SF3B1 and myelodysplastic syndrome: An entity of MDS with mutated SF3B1 (MDS-SF3B1) has been included in the two new classifications of myeloid neoplasms recently published: the World Health Organization (WHO) 2022 classification and the International Consensus Classification (ICC) 2022 [107,108].